Femasys is trading at $2.68, down -10.07%, amid broader risk-off trading.
- No new company-specific announcement was identified for September 8, 2026; recent listed company news includes the August 26 UNC Health partnership and August financing activity.
- The Dow is down more than 1%, while oil-price and geopolitical concerns pressure markets.
- The sharper-than-market decline may reflect small-cap volatility, but available evidence points primarily to global sentiment rather than a confirmed company catalyst.